Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Apomab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Apomab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Apomab. |
| Estrone | Estrone may increase the thrombogenic activities of Apomab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Apomab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Apomab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Apomab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Apomab. |
| Estriol | Estriol may increase the thrombogenic activities of Apomab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Apomab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Apomab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Apomab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Apomab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Apomab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Apomab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Apomab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Apomab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Apomab. |
| Equol | Equol may increase the thrombogenic activities of Apomab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Apomab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Apomab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Apomab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Apomab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Apomab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Apomab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Apomab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Apomab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Apomab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Apomab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Apomab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Apomab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Apomab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Apomab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Apomab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Apomab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apomab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apomab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Apomab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apomab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Apomab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Apomab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Apomab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apomab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apomab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Apomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apomab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apomab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Apomab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apomab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Apomab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Apomab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Apomab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apomab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Apomab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Apomab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Apomab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Apomab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Apomab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Apomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Apomab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Apomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Apomab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Apomab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Apomab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Apomab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Apomab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Apomab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Apomab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Apomab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Apomab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Apomab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Apomab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Apomab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Apomab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Apomab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Apomab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Apomab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Apomab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Apomab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Apomab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Apomab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Apomab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Apomab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Apomab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Apomab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Apomab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Apomab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Apomab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Apomab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Apomab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Apomab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Apomab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Apomab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Apomab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Apomab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Apomab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Apomab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Apomab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Apomab. |